-
Express reduces the bleeding rate of hemophilia patients by about 90%, and the monthly RNAi therapy reaches the phase 3 clinical endpoint
Time of Update: 2021-12-05
The latest abstract of the ASH annual meeting showed that in patients who do not express inhibitors that inhibit exogenous coagulation factors in the body, a monthly dose of fitusiran significantly reduces the annual bleeding rate (ABR) of patients compared with receiving concentrated coagulation factors on demand.
-
Celiniso combined with Vd regimen can achieve excellent efficacy in all subgroups of R/R MM
Time of Update: 2021-12-05
Figure 1: Patients with different cytogenetic subgroups between the two treatment groups have high risk of PFS (78.
Patients in the standard-risk and high-risk groups who received XVd had a lower disease progression (PD) rate than those treated with Vd .
-
Roche announced the latest results of a variety of bispecific antibodies and ADC therapies, which is expected to redefine the standard treatment for blood cancer
Time of Update: 2021-12-05
▲Introduction to Glofitamab (picture source: Roche official website) The clinical trial data described in the ASH summary shows that as a single-agent therapy, glofitamab has achieved an ORR of 81% in early clinical trials for the treatment of patients with relapsed/refractory follicular lymphoma (n =43) and 70% complete metabolic response rate (CMR) .
-
2021 ASH Voice of China Prof. Weilai Zhao’s team: Interim results of PI3Kδ inhibitor Parsaclisib in the treatment of Chinese patients with relapsed/refractory FL
Time of Update: 2021-12-05
Among the 36 patients with evaluable safety, the most common "treatment period" adverse events (TEAE) were decreased neutrophil count (36.
-
Express 100% of patients get objective relief, and the latest clinical results of ready-to-use natural killer cell therapy are positive
Time of Update: 2021-12-05
▎Editor of WuXi AppTec Content Team On November 22, 2021, Affimed announced that its cord blood-derived natural killer cell therapy was pre-combined with the innate cell engager (ICE) AFM13.
-
2021 ASH blockbuster Late-Breaking Abstracts summary
Time of Update: 2021-12-05
Speaker: Lynn Malec Unit: Versiti Blood Research Institute, Milwaukee, WI Reporting time: Tuesday, December 14, 2021, 9:00 AM- 10:30 AM06 Abstract Number: LBA-6 Topic: Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study.
-
Express One-time Gene Therapy Gets FDA Priority Review Qualification, Treats β-thalassemia
Time of Update: 2021-12-05
▎WuXi AppTec content team editor November 22, 2021, bluebird bio announced that the US FDA has granted priority review qualification for the biologics license application (BLA) for gene therapy betibeglogene autotemcel (beti-cel), which requires acceptance for treatment Beta thalassemia patients with routine red blood cell transfusion .
-
2021 ASH blockbuster Fitusiran preventive treatment of patients with type A or type B hemophilia patients with the efficacy and safety of the first batch of results announced
Time of Update: 2021-12-05
Research Methods This phase III, multi-country, multi-center, randomized, open-label study evaluated the efficacy and safety of fitusiran in the treatment of male patients with severe hemophilia A or B who are ≥12 years old and without inhibitors.
-
2021 ASH is the first to see Professor Song Yuqin: MRG001's Phase Ia research data is officially announced
Time of Update: 2021-12-05
Among them, Professor Song Yuqin, Department of Lymphatic Oncology, Peking University Cancer Hospital, published an abstract paper titled "Phase Ia Study of Dose Escalation of Anti-CD20 Antibody Conjugate Drug MRG001 in Relapsed/Refractory Advanced Non-Hodgkin's Lymphoma" .
-
ADC of new vision multiple myeloma treatment for myeloma
Time of Update: 2021-12-05
Ideally, after the ADC drug enters the body, the antibody part specifically binds to the target cell expressing the tumor antigen.
-
Exp Hematol: Immune components after chemotherapy-induced acute myeloid leukemia and their relationship with hematological recovery
Time of Update: 2021-12-04
Figure 2: The frequency of CD4CM T and NK cells is related to the recovery of neutrophils after AML chemotherapy .
-
Prevention, individualized prevention, and emerging therapies continue to develop hemophilia A treatment
Time of Update: 2021-12-04
The study included 72 Chinese male patients with hemophilia A (FVIII level ≤ 2%), who first received 6 months of rAHF-PFM on-demand treatment, and then received 6 months of rAHF-PFM preventive treatment (20-40 IU/kg , Once every 48±6 hours), evaluate the patient’s annual bleeding rate (ABR) and the hemostatic efficacy and safety of rAHF-PFM .
-
Haemophilia: Vaccination of children with inherited bleeding disorders: Does the use of plasma and factors affect the response to the vaccine
Time of Update: 2021-12-04
This prospective observational study included children between the ages of 2 and 17 who were diagnosed with genetic factor deficiency .
This prospective observational study included children between the ages of 2 and 17 who were diagnosed with genetic factor deficiency .
-
AJH: Allogeneic SARS-CoV-2 vaccination for patients with B-cell lymphoma
Time of Update: 2021-12-04
According to the evaluation of Roche Elecsys against sars-CoV-2S , the patient lacked sufficient spike antibody response to the initial two-dose mRNA series, and independently sought for heterologous vaccination, which is a semi-quantitative target against spike protein receptor binding domain Total antibody detection method .
-
Transfusion: Individualized risk trajectory for repeated iron-related adverse outcomes in blood donors
Time of Update: 2021-12-03
Although fingertip hemoglobin is required and the minimum blood donation interval is 56 days, repeated donations can still cause and exacerbate iron deficiencyA foreign team used data from the REDS-II donor iron status evaluation study to develop a multi-class prediction model to estimate hemoglobin delay and the competitive risk of collecting blood from donors with sufficient hemoglobin but low or lack of potential iron reserves .
-
BJH: Can Ruxotinib avoid splenectomy in patients with thalassemia?
Time of Update: 2021-12-03
Ruxotinib (JAK1 and -2 inhibitor) has been approved for the treatment of primary myelofibrosis (MF), polycythemia vera (PV) post-MF and primary thrombocythemia MF , the main purpose is to reduce Small spleen size .
In all four patients, spleen size and physical symptoms related to splenomegaly were significantly reduced .
-
J Clin Oncol: The efficacy of ibrutinib combined with rituximab in the first-line treatment of elderly patients with mantle cell lymphoma
Time of Update: 2021-12-03
LymphomaThis is a single-center, single-arm phase 2 clinical trial to study the effectiveness and effectiveness of ibrutinib and rituximab (IR) in the treatment of previously untreated elderly MCL patients (≥65 years of age) Security .
-
JAHA: Efficacy and safety analysis of NOAC and warfarin in patients with atrial fibrillation and aortic stenosis
Time of Update: 2021-12-03
Recently, the heart blood vessels published a research article on the disease areas authoritative magazine JAHA, the purpose of the study was to assess the effects of warfarin and NOAC with aortic stenosis in patients with AF thromboembolism and major bleeding .
-
BJH: Dexamethasone-mediated inhibition of Notch signaling blocks the interaction between leukemia and mesenchymal stromal cells
Time of Update: 2021-12-01
Using dexamethasone or Notch inhibitors to target the interaction of leukemia cells and AML MSCs may further improve treatment outcomes for AML patients Original source:Original source:Ahmed, HMM, Nimmagadda, SC, Al-Matary, YS, Fiori, M.
-
AJH: Freeze-dried platelets are a promising alternative for patients with hemorrhagic thrombocytopenia due to hematological malignancies
Time of Update: 2021-12-01
Thrombus represents a potential replacement strategy for platelet transfusionThe research team conducted an open-label phase 1 study to study single-dose allogeneic thrombi at 3 dose levels in 3 cohorts.
Twenty-four hours after the infusion, 12 patients (50%) had a clinically significant increase in platelet count .
